REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment-Reference-Cited by-同舟云学术

REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment

Published:2023-05 Issue:5 Volume:24 Page:e219-e227
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ghorani Ehsan,Quartagno Matteo,Blackhall Fiona,Gilbert Duncan C,O'Brien Mary,Ottensmeier Christian,Pizzo Elena,Spicer James,Williams Alex,Badman Philip,Parmar Mahesh K B,Seckl Michael J

Publisher

Elsevier BV

Subject

Oncology

Reference77 articles.

1. Too much medicine?;Moynihan;BMJ,2002

2. Too much medicine: the challenge of finding common ground;Macdonald;BMJ,2015

3. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer;Fisher;N Engl J Med,2002

4. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial;Coles;Lancet,2017

5. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial;Iveson;Lancet Oncol,2018

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preventive therapy: can tuberculosis efforts learn anything from the leprosy approach?;The Lancet Global Health;2024-09

2. Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition;British Journal of Cancer;2024-06-17

3. Reducing the environmental impact of immunotherapy treatment;The Lancet Oncology;2024-06

4. 204 REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design;Lung Cancer;2024-04

5. Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin’s lymphoma;Cell Reports Medicine;2024-02